HCPLive Network
  • Chronic Pain Peer Exchange Video Series
  • Family Practice Recertification
  • Internal Medicine World Report
  • Multiple Sclerosis Peer Exchange Video Series
  • Cardiology Review
  • Physician’s Money Digest
  • Surgical Rounds
Latest Specialty Headlines
Wednesday, September 17, 2014
By Adam Hochron
The outbreak of the Ebola virus in West Africa is showing no signs of slowing down. As a result, President Barack Obama announced Tuesday that the United States would be getting even more directly involved in the effort to contain the outbreak and prevent it from spreading any further.
Tuesday, September 16, 2014
By HCPLive staff
Movantik (naloxegol), an oral peripherally acting mu-opioid receptor antagonist, has been approved by the FDA for the treatment of opioid-induced constipation in adults with chronic non-cancer pain.
Wednesday, September 17, 2014
By HCPLive staff
Researchers have developed a math model that can accurately predict the progression from nephritis to interstitial fibrosis in patients with systemic lupus erythematosus.
Wednesday, September 17, 2014
By Adam Hochron
Recent studies looking at neural response in patients with fibromyalgia have shown that people with this condition may have hypersensitivity to non-painful stimuli.
Wednesday, September 17, 2014
By Rachel Lutz
Adverse drug events involving psychiatric medications are not uncommon in emergency departments, according to a study published in JAMA Psychiatry.
Wednesday, September 17, 2014
By Amy Jacob
Researchers at Beth Israel Deaconess Medical Center (BIDMC) reported that proactive monitoring of dose adjustments of infliximab (IFX), one of the 4 anti-TNF-alpha proteins used to treat inflammatory diseases like Crohn’s disease (CD), ulcerative colitis (UC), and inflammatory bowel disease (IBD), could prolong the effectiveness of treatment.
Wednesday, September 17, 2014
The number of Americans dying from accidental overdoses of opioid analgesics jumped significantly from 1999 to 2011, according to a September data brief published by the US Centers for Disease Control and Prevention's National Center for Health Statistics.
Wednesday, September 17, 2014
About 14.5 million US cancer survivors are alive today, compared to just three million in 1971, the American Association for Cancer Research reported Tuesday.
Wednesday, September 17, 2014
Exposure in the womb to household chemicals known as phthalates might increase a child's future risk of developing asthma, according to research published online Sept. 17 in Environmental Health Perspectives.
Wednesday, September 17, 2014
A simple urine test can routinely spot human papillomavirus, according to research published online Sept. 16 in The BMJ.
Email Signup
Physician's Money Digest
At no time in history have any people lived as well as we Americans have been living for the past 30 years. Now that we are in a period of economic stagnation, millions are paying a steep price for living the high life and with such abandon.
A coalition of 17 medical associations and trade groups is calling on the US Department of Health and Human Services to amend its reporting 2015 requirements for the Medicare and Medicaid Electronic Health Record Incentive Program.
Product News
The FDA has approved Baxter’s Rixubis [Coagulation Factor IX (Recombinant)], an intravenous prophylactic treatment intended to control and prevent bleeding episodes and assist with perioperative management for children 12 years and younger with hemophilia B.
Contrave (naltrexone hydrochloride and bupropion hydrochloride extended-release tablets) is a treatment option for chronic weight management in addition to a reduced-calorie diet and physical activity.
GeNeuro, a Swiss company specializing in promising therapies for neurological disorders, recently announced positive results from a Phase IIa study of a new drug for multiple sclerosis (MS).
A new test recently approved by the US Food and Drug Administration could go a long way in helping identify patients who could suffer acute kidney injury following hospitalization.
The US Food and Drug Administration (FDA) gave a breakthrough therapy designation to pimavanserin (Nuplazid/Acadia Pharmaceuticals) for the treatment of Parkinson’s Disease. The drug, a proprietary small molecule that is a selective serotonin inverse agonist, may also hold be useful in other mental illnesses, including Alzheimer’s Disease and schizophrenia, according to Acadia.
HCPLive Poll
Twitter Advice
Have you ever given medical or financial advice on Twitter?